Robert J.M. Klautz

TL;DR: Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means.

TL;DR: Residual mitral regurgitation was absent/minimal at 2-year follow-up, associated with a significant reduction in left atrial dimension and LV reverse remodeling and excellent results of combined restrictive annuloplasty and CABG were obtained.

TL;DR: Intermediate-term cutoff values for left ventricular reverse remodeling proved to be predictors for late mortality, and for patients with preoperative LVEDD of 65 mm or less, restrictive mitral annuloplasty with revascularization provides a cure for ischemic mitral regurgitation and heart failure; however, whenLVEDD exceeds 65 mm, outcome is poor and a ventricular approach should be considered.

TL;DR: In severe AS patients, impaired LV S-and-SR existed although LVEF was preserved, and after AVR, a significant S- and-SR improvement in all the three directions was observed, suggesting subtle changes in LV contractility can be detected by 2D-STI.

TL;DR: Stringent restrictive mitral annuloplasty with or without revascularization provides excellent clinical results with acceptable mortality, and preoperative left ventricular end-diastolic dimension is identified as the single best factor in predicting occurrence of reverse remodeling.